Watson to Present at 2013 Goldman Sachs Healthcare CEOs Unscripted: A View from the Top

  Watson to Present at 2013 Goldman Sachs Healthcare CEOs Unscripted: A View
                                 from the Top

PR Newswire

PARSIPPANY, N.J., Dec. 20, 2012

PARSIPPANY, N.J., Dec. 20, 2012 /PRNewswire/ -- Watson Pharmaceuticals, Inc.
(NYSE: WPI), a leading specialty pharmaceutical company, announced today that
Paul Bisaro, Watson's President and Chief Executive Officer, will provide an
overview and update of the Company's business at the 2013 Goldman Sachs
Healthcare CEOs Unscripted: A View from the Top conference on Thursday,
January 3, 2013 at 1:45 pm EST at the Goldman Sachs Conference Center in New
York. The presentation will be webcast live and can be accessed on Watson
Pharmaceuticals' Investor Relations Web site at http://ir.watson.com. The
webcast can also be accessed at the following URL:


An archived version will be available approximately one hour after the live
presentation ends and can be accessed at the same locations for 90 days.

About Watson Pharmaceuticals, Inc.

Watson Pharmaceuticals,Inc. (NYSE: WPI) is a global, integrated specialty
pharmaceutical company focused on developing, manufacturing and distributing
generic, brand and biosimilar products. The Company has global and U.S.
headquarters in Parsippany, New Jersey, USA, and international headquarters in
Zug, Switzerland.

Watson is the world's third-largest generics prescription drug manufacturer,
with more than 750 products marketed globally through operations in more than
60 countries. Watson's global branded pharmaceutical business develops and
markets products principally in Urology and Women's Health, and iscommitted
to developing and marketing biosimilars products in Women's Health, Oncology
and other therapeutic categories. In addition, Watson is the fourth-largest
U.S. generic pharmaceutical product distributor through its Anda, Inc.
business, and also develops and out-licenses generic pharmaceutical products
outside of the U.S. through its Medis third-party business. Watson has
announced that it will adopt a new global name – Actavis – effective in 2013.

For press release and other company information, visit Watson Pharmaceuticals'
Web site at http://www.watson.com.

CONTACTS: Investors:
          Lisa DeFrancesco
          (862) 261-7152
          Charlie Mayr
          (862) 261-8030

(Logo: http://photos.prnewswire.com/prnh/20100121/LA41294LOGO )

SOURCE Watson Pharmaceuticals, Inc.

Website: http://www.watson.com
Press spacebar to pause and continue. Press esc to stop.